These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 19560103)

  • 1. Scales as outcome measures for Alzheimer's disease.
    Black R; Greenberg B; Ryan JM; Posner H; Seeburger J; Amatniek J; Resnick M; Mohs R; Miller DS; Saumier D; Carrillo MC; Stern Y
    Alzheimers Dement; 2009 Jul; 5(4):324-39. PubMed ID: 19560103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease.
    Truffinet P; Bordet R; Ménard J
    Therapie; 2009; 64(3):139-8. PubMed ID: 19671425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partnership between academia and industry for drug discovery in Alzheimer's disease.
    Ivinson AJ; Lane R; May PC; Hosford DA; Carrillo MC; Siemers ER
    Alzheimers Dement; 2008 Mar; 4(2):80-8. PubMed ID: 18631952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome measures in multiple sclerosis clinical trials.
    Andersson PB; Goodkin DE
    Baillieres Clin Neurol; 1997 Oct; 6(3):409-28. PubMed ID: 10101581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer's disease: it is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's disease.
    Doody RS
    Alzheimers Dement; 2009 Mar; 5(2):133-6. PubMed ID: 19328443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring treatment response in Alzheimer's disease clinical trials.
    Caban-Holt A; Bottiggi K; Schmitt FA
    Geriatrics; 2005 Jun; Suppl():3-8. PubMed ID: 16025769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral effects of current Alzheimer's disease treatments: a descriptive review.
    Cummings JL; Mackell J; Kaufer D
    Alzheimers Dement; 2008 Jan; 4(1):49-60. PubMed ID: 18631950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural neuroimaging outcomes in clinical dementia trials, with special reference to disease modifying designs.
    Scheltens P; Barkhof F
    J Nutr Health Aging; 2006; 10(2):123-8; discussion 129-30. PubMed ID: 16554946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring cognitive change in Alzheimer's disease clinical drug trials.
    Harrison JE
    J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cognitive testing in disease modifying AD trials.
    Visser PJ
    J Nutr Health Aging; 2006; 10(2):131-2; discussion 132-3. PubMed ID: 16554947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early clinical trials in Alzheimer's disease: selection and evaluation of drug candidates.
    Reines SA
    Prog Clin Biol Res; 1989; 317():1283-90. PubMed ID: 2690095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing health economic outcome in Alzheimer's disease clinical trials.
    Jonsson L
    J Nutr Health Aging; 2007; 11(4):353-5. PubMed ID: 17653498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global issues in drug development for Alzheimer's disease.
    Doody RS; Cole PE; Miller DS; Siemers E; Black R; Feldman H; Schindler R; Graham S; Heath T; Khachaturian AS; Evans R; Carrillo MC
    Alzheimers Dement; 2011 Mar; 7(2):197-207. PubMed ID: 21414556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Who may benefit from disease-modifying studies in Alzheimer's disease?
    Gauthier S; Poirier J
    Alzheimers Dement; 2009 Mar; 5(2):147-8. PubMed ID: 19328447
    [No Abstract]   [Full Text] [Related]  

  • 15. Generic and disease-specific measures of quality of life in patients with mild Alzheimer's disease.
    Bhattacharya S; Vogel A; Hansen ML; Waldorff FB; Waldemar G
    Dement Geriatr Cogn Disord; 2010; 30(4):327-33. PubMed ID: 20924186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The epidemiology of Alzheimer's disease: laying the foundation for drug design, conduct, and analysis of clinical trials.
    Yaffe K; Tocco M; Petersen RC; Sigler C; Burns LC; Cornelius C; Khachaturian AS; Irizarry MC; Carrillo MC
    Alzheimers Dement; 2012 May; 8(3):237-42. PubMed ID: 22546356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial.
    Wong VS
    Neurology; 2007 Aug; 69(8):809; author reply 809-10. PubMed ID: 17709718
    [No Abstract]   [Full Text] [Related]  

  • 18. Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." A proposal to increase participation in Alzheimer's disease clinical trials.
    Ryan JM; Schneider G; Jacobsen JS
    Alzheimers Dement; 2009 Mar; 5(2):140-2. PubMed ID: 19328445
    [No Abstract]   [Full Text] [Related]  

  • 19. [Therapeutic trials in Alzheimer disease. Selection--recruitment and stratification].
    Chaumet-Riffaud P; Wolmark Y; Péré JJ; Goulley F
    Therapie; 1993; 48(3):201-5. PubMed ID: 8140558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
    Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
    J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.